Higher viscosity participates in the regulation of coronary flow via nitric oxide and indomethacin-sensitive contracting factor

Can J Physiol Pharmacol. 2004 Dec;82(12):1096-102. doi: 10.1139/y04-127.

Abstract

Few studies have reported on the association of viscosity with coronary circulation. We evaluated the change in coronary flow after dextran was added to a perfusion solution to increase viscosity in isolated rat hearts. We also measured NOx- production induced by the change in shear stress in the coronary effluent, as a marker of NO synthesis. The baseline coronary flow was not influenced by the presence of either the cyclooxygenase inhibitor indomethacin, the thromboxane A2 (TXA2)-prostaglandin H2 (PGH2) receptor antagonist ONO-3708, or the TXA2 synthase inhibitor OKY-046. After exposure to solution containing 0.5% dextran, the coronary flow first decreased and then gradually increased until 10 min. The initial decrease in coronary flow was inhibited by indomethacin, ONO-3708, and OKY-046 individually. The gradual increase was completely inhibited by the NO inhibitor L-NAME, but not by indomethacin or ONO-3708. OKY-046 partially inhibited the increase. NOx- levels in the effluent were higher after the dextran solution was administered, and the increased NOx- levels were inhibited by L-NAME. The increased NOx- levels were not inhibited by inhibitors of the cyclooxygenase pathway. It appears that a higher viscosity of perfusion solution induced a gradual increase in NO production and was associated with increased production of indomethacin-sensitive contracting factor.

MeSH terms

  • Animals
  • Blood Viscosity / drug effects
  • Blood Viscosity / physiology*
  • Coronary Circulation / physiology*
  • Cyclooxygenase Inhibitors / pharmacology*
  • Dextrans / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Indomethacin / pharmacology*
  • Male
  • Methacrylates / pharmacology
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase Type III
  • Rats
  • Rats, Inbred WKY
  • Rheology
  • Thromboxane A2 / analogs & derivatives*
  • Thromboxane A2 / pharmacology

Substances

  • Cyclooxygenase Inhibitors
  • Dextrans
  • Enzyme Inhibitors
  • Methacrylates
  • Nitric Oxide
  • Thromboxane A2
  • ONO 3708
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • ozagrel
  • NG-Nitroarginine Methyl Ester
  • Indomethacin